801 related articles for article (PubMed ID: 19405003)
81. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
[TBL] [Abstract][Full Text] [Related]
82. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis.
Alcântara AC; Leite CA; Leite AC; Sidrim JJ; Silva FS; Rocha FA
J Rheumatol; 2014 Feb; 41(2):338-44. PubMed ID: 24334641
[TBL] [Abstract][Full Text] [Related]
83. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
[TBL] [Abstract][Full Text] [Related]
84. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.
Ruperto N; Nikishina I; Pachanov ED; Shachbazian Y; Prieur AM; Mouy R; Joos R; Zulian F; Schwarz R; Artamonova V; Emminger W; Bandeira M; Buoncompagni A; Foeldvari I; Falcini F; Baildam E; Kone-Paut I; Alessio M; Gerloni V; Lenhardt A; Martini A; Hanft G; Sigmund R; Simianer S;
Arthritis Rheum; 2005 Feb; 52(2):563-72. PubMed ID: 15692986
[TBL] [Abstract][Full Text] [Related]
85. The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
Boyko Y; Hrytsiuk I; Consolaro A; Bovis F; Ruperto N;
Rheumatol Int; 2018 Apr; 38(Suppl 1):403-409. PubMed ID: 29637352
[TBL] [Abstract][Full Text] [Related]
86. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
[TBL] [Abstract][Full Text] [Related]
87. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate.
Chickermane PR; Khubchandani RP
Clin Exp Rheumatol; 2015; 33(2):287-92. PubMed ID: 25738527
[TBL] [Abstract][Full Text] [Related]
88. [Diagnosis and treatment of juvenile idiopathic arthritis (JIA)].
Takei S
Nihon Rinsho; 2016 Jun; 74(6):1028-34. PubMed ID: 27311197
[TBL] [Abstract][Full Text] [Related]
89. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
Pincus T
Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
[TBL] [Abstract][Full Text] [Related]
90. Clinical profile and juvenile arthritis damage index in children with juvenile idiopathic arthritis: A study from a tertiary care center in south India.
Menon NVB; Peethambaran G; Puthiyapurayil AT; Nambudakath C; Arakkal R
Int J Rheum Dis; 2018 Apr; 21(4):871-879. PubMed ID: 27309679
[TBL] [Abstract][Full Text] [Related]
91. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
[TBL] [Abstract][Full Text] [Related]
92. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score.
van Rossum MA; Boers M; Zwinderman AH; van Soesbergen RM; Wieringa H; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
Arthritis Rheum; 2005 Sep; 52(9):2865-72. PubMed ID: 16142707
[TBL] [Abstract][Full Text] [Related]
93. Dynamic knee joint function in children with juvenile idiopathic arthritis (JIA).
Hansmann S; Benseler SM; Kuemmerle-Deschner JB
Pediatr Rheumatol Online J; 2015; 13():8. PubMed ID: 25829894
[TBL] [Abstract][Full Text] [Related]
94. Juvenile Idiopathic Arthritis.
Barut K; Adrovic A; Şahin S; Kasapçopur Ö
Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
[TBL] [Abstract][Full Text] [Related]
95. Serum Calprotectin Levels in Different Subtypes of Juvenile Idiopathic Arthritis (JIA) and Its Correlation with Quantitative CRP and JADAS-27.
Remthangpuii F; Maheshwari A; Gulati S; Sharma S; Mahto D; Chandra J
Indian J Pediatr; 2023 Dec; 90(12):1177-1181. PubMed ID: 36763251
[TBL] [Abstract][Full Text] [Related]
96. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Berman A; Calvo Penadés I; Antón J; Ávila-Zapata F; Cuttica R; Horneff G; Foeldvari I; Keltsev V; Kingsbury DJ; Viola DO; Joos R; Lauwerys B; Paz Gastañaga ME; Rama ME; Wouters C; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Miraval T; Ally MMTM; Rubio-Pérez N; Solau Gervais E; van Zyl R; Li X; Nys M; Wong R; Banerjee S; Lovell DJ; Martini A; Ruperto N;
Arthritis Rheumatol; 2018 Jul; 70(7):1144-1154. PubMed ID: 29481737
[TBL] [Abstract][Full Text] [Related]
97. Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study.
Arnstad ED; Rypdal V; Peltoniemi S; Herlin T; Berntson L; Fasth A; Nielsen S; Glerup M; Ekelund M; Zak M; Aalto K; Nordal E; Romundstad PR; Rygg M;
Arthritis Care Res (Hoboken); 2019 Jul; 71(7):961-969. PubMed ID: 30055093
[TBL] [Abstract][Full Text] [Related]
98. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
[TBL] [Abstract][Full Text] [Related]
99. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
El Miedany Y; Youssef SS; El Gaafary M
J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
[TBL] [Abstract][Full Text] [Related]
100. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
Lovell DJ; Dare JA; Francis-Sedlak M; Ball J; LaMoreaux BD; Von Scheven E; Reinhardt A; Jerath R; Alpan O; Gupta R; Goldsmith D; Zeft A; Naddaf H; Gottlieb B; Jung L; Holt RJ
Pediatr Rheumatol Online J; 2018 Jun; 16(1):41. PubMed ID: 29941047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
